Associated Genetic Biomarkers
BRAF G464E is present in 0.01% of AACR GENIE cases, with colorectal neuroendocrine carcinoma, conventional glioblastoma multiforme, head and neck squamous cell carcinoma, melanoma, and T-cell lymphoblastic leukemia/lymphoma having the greatest prevalence .
BRAF G464E serves as an inclusion eligibility criterion in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials that contain BRAF G464E as an inclusion criterion, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open).
Trials with BRAF G464E in the inclusion eligibility criteria most commonly target malignant solid tumor .
Belvarafenib, binimetinib, and encorafenib are the most frequent therapies in trials with BRAF G464E as an inclusion criteria .
Significance of BRAF G464E in Diseases
Malignant Solid Tumor +
BRAF is altered in 6.59% of malignant solid tumor patients with BRAF G464E present in 0.0% of all malignant solid tumor patients .
BRAF G464E is an inclusion criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain BRAF G464E and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.